Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Generic

    Jump to

    • Trump's 100% tariff on branded drugs: Exporters assessing impact on complex generics

      Pharmexcil, the sector's leading export body, said it is prudent to stay prepared for any future policy shift and build risk-mitigation strategies.

    • A year of hits and misses for the Indian pharma sector

      Even as pharma exports grew in terms of volumes and value, the cloud of inadequate hygiene and safety in some pharma companies continued to hang over the industry, forcing the government to put in place more stringent inspections and processes.

    • Glenmark launches generic version of diuretic with $16.5-million market

    • Glenmark gets USFDA nod for generic acne treatment gel

    • Strides Shasun receives USFDA tentative nod for Fingolimod

    • Trump intervention in pharma may affect Indian suppliers: PwC

    • Dr Reddy's launches generic Lamotrigine tablets in US

    • Pharmaceutical industry growth to remain moderate, says Icra

    • We are planning 6-8 new launches this fiscal yr: Alembic Pharma

    • Hikma to buy Boehringer's US generics unit for $2.65 bn

    • Hope for Hepatitis C-affected Indians

    • 'Ranbaxy's Nexium generic loss may up Cipla's EPS 3-5%'

    • Ranbaxy forfeits 180 days exclusivity for stomach drugs

    • Panacea enters into alliance with Canada based Apotex Inc

    • Strides Arcolab up 3%, Macquarie says dividend to drive it

    • Cipla at new high, up 8%; respiratory drug launch in UK key

    • Ranbaxy, Teva settle US anti-trust probe for $3,00,000

    • Q2 nos drive Aurobindo Pharma to 34-month high, up 10%

    • Lupin to rely on Antara sales to rebuild brand: MD

      After receiving the USFDA nod for its supplemental new drug application for Antara capsules on Tuesday, Lupin will now focus on building back its brand by gaining its lost market share.

    • Expect $100m revenue via Elores by FY18: Venus Remedies

      In an interview to CNBC-TV18, Dheeraj Aggarwal, CFO, Venus Remedies spoke about revenue prospects of Elores, for which the company recently won patent from Japan.

    • Glenmark Pharma Q4 beats street, net up 11% to Rs 167 cr

      Glenmark Pharma beat street expectation on Tuesday with a consolidated net profit of Rs 167 crore in Jan-March, up 11 percent from a year ago. Net sales gained 25 percent to Rs 1,335 crore.

    • Contraceptives basket can fetch $150m from US sales: Lupin

      Pharma major Lupin expects sales in the US to touch at least USD 150 million per quarter going ahead, S Ramesh, CFO, said on Tuesday.

    • Ranbaxy rises after Nomura upgrades stock to 'buy'

      Ranbaxy Laboratories shares gained 2 percent on Monday morning after Nomura Financial Advisory and Securities India upgraded the pharma major to "buy" from "neutral." The brokerage also raised its target price on the stock to Rs 475 from Rs 415.

    • Enaltec bets on niche APIs to earn Rs 400cr by 2016

      Entrepreneurship is not for the faint hearted and it is about taking a leap of faith. This is what drove three young men to leave their high profile jobs to start up on their own in the USD 80 billion healthcare market in India.

    • Dr Reddy's launches oncology injection in US

      Generics drugs maker Dr Reddy's Laboratories on Tuesday said it has launched Zoledronic Acid injection 4mg/5ml in the US market following approval by the US Food and Drugs Administration.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347